Lanreotid

When ATH:
H01CB03

Characteristic.

The synthetic somatostatin analogue.

Pharmacological action.
Somatostatinopodobnoe.

Application.

Akromegalija, endocrine tumors of the gastroenteropancreatic system (symptomatic treatment), complications after pancreatic surgery (prevention), acute pancreatitis, persistent diarrhea in AIDS patients.

Contraindications.

Hypersensitivity, pregnancy, lactation.

Pregnancy and breast-feeding.

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects.

Anorexia, nausea, vomiting, abdominal pain, diarrhea, celiac disease, change in glucose tolerance, abnormal liver function, formation of stones in the biliary tract (prolonged use), increased secretion of somatotropin by pituitary tumors, pain, itch, burning at the injection site.

Dosing and Administration.

/ M. Doses and mode of administration are selected individually. Treatment begins with a test injection (if it is ineffective, further therapy is not advisable) and evaluate response (dynamics of growth hormone secretion, symptoms, associated with carcinoid tumor, etc.). For acromegaly and carcinoid tumors, it is prescribed according to 30 mg every 10–14 days.

Precautions.

Treatment should be carried out in specialized institutions. Patients with diabetes mellitus should be prescribed under constant monitoring of blood glucose levels. (insulin dose should be reduced, usually, on 25%). For carcinoid tumors of the gastrointestinal tract, therapy begins after the elimination of intestinal obstruction; An ultrasound scan of the gallbladder is mandatory (every 6 Months). The appearance of severe and prolonged steatorrhea requires the appointment of enzyme replacement therapy.